Ovarian Cancer Clinical Trial

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Summary

This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.

View Full Description

Full Description

B9991046 is a master protocol that will consist of sub-studies from the following parent studies:

B9991001 - NCT02603432 B9991004 - NCT02554812 B9991005 - NCT02584634 B9991009 - NCT02580058 B9991023 - NCT03317496 B9991025 - NCT03330405 B9991027 - NCT03472560 B9991032 - NCT03565991

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Any participant who is receiving study treatment and deriving significant clinical benefit or is in the safety and/or survival follow-up period in a Pfizer-sponsored Avelumab Parent Study.
Participants must agree to follow the reproductive criteria.
Participants must be willing and able to comply with all scheduled visits, treatment plan, and other study procedures.

Exclusion Criteria:

Female participants who are pregnant or breastfeeding.
Any medical reason that, in the opinion of the Investigator or Sponsor, precludes the participant from inclusion in the study.

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

262

Study ID:

NCT05059522

Recruitment Status:

Recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 48 Locations for this study

See Locations Near You

Highlands Oncology Group, PA
Fayetteville Arkansas, 72703, United States
Highlands Oncology Group, PA
Rogers Arkansas, 72758, United States
Highlands Oncology Group, PA
Springdale Arkansas, 72762, United States
UCLA Hematology/Oncology - Administrative Office
Los Angeles California, 90024, United States
Ronald Reagan UCLA Medical Center - Drug Information Center, Pharmaceutical Services
Los Angeles California, 90095, United States
UCLA Hematology/Oncology
Los Angeles California, 90095, United States
MSK Basking Ridge
Basking Ridge New Jersey, 07920, United States
MSK Monmouth
Middletown New Jersey, 07748, United States
MSK Bergen
Montvale New Jersey, 07645, United States
MSK Commack
Commack New York, 11725, United States
MSK Westchester
Harrison New York, 10604, United States
Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy
Long Island City New York, 11101, United States
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York New York, 10021, United States
Memorial Sloan Kettering Cancer Center 53rd street.
New York New York, 10022, United States
Memorial Sloan Kettering Cancer Center
New York New York, 10065, United States
MSK Nassau
Uniondale New York, 11553, United States
Hospital of the University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States
The University of Texas MD Anderson Cancer Center
Houston Texas, 77030, United States
The Prince Charles Hospital
Chermside Queensland, 4032, Australia
Grand Hôpital de Charleroi
Charleroi Hainaut, 6000, Belgium
UZ Gent
Gent Oost-vlaanderen, 9000, Belgium
Cross Cancer Institute
Edmonton Alberta, T6G 1, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site
Kingston Ontario, K7L 2, Canada
Aalborg Universitetshospital, Syd
Aalborg Nordjylland, 9000, Denmark
Institut de Cancérologie de Lorraine Alexis Vautrin
Vandoeuvre-lès-Nancy Lorraine, 54519, France
Országos Onkológiai Intézet
Budapest , 1122, Hungary
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan Milano, 20133, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi
Ancona , 60126, Italy
AOU Policlinico Umberto I
Roma , 00161, Italy
National Cancer Center Hospital
Chuo-ku Tokyo, 104-0, Japan
Japanese Foundation for Cancer Research
Koto Tokyo, 135-8, Japan
National Hospital Organization Kyushu Cancer Center
Fukuoka , 811-1, Japan
Oita University Hospital
Yufu Ōita, 879-5, Japan
Gachon University Gil Medical Center
Namdong-gu Incheon-gwangyeoksi [incheon], 21565, Korea, Republic of
National Cancer Center
Goyang-si Kyǒnggi-do, 10408, Korea, Republic of
Seoul National University Bundang Hospital
Seongnam Kyǒnggi-do, 13620, Korea, Republic of
Asan Medical Center
Seoul Seoul-teukbyeolsi [seoul], 05505, Korea, Republic of
Samsung Medical Center
Seoul Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of
Samsung Medical Center
Seoul Seoul-teukbyeolsi [seoul], 06351, Korea, Republic of
Centralny Szpital Kliniczny MSWiA w Warszawie
Warszawa , 02-50, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie
Warszawa , 02-78, Poland
GBUZ SK Pyatigorsk Interdistrict Oncology dispensary
Pyatigorsk Stavropol'skiy KRAY, 35750, Russian Federation
Hospital Universitari Vall d'Hebron
Barcelona Barcelona [barcelona], 08035, Spain
Hospital Clínic de Barcelona
Barcelona Barcelona [barcelona], 08036, Spain
Hospital Universitari Vall d'Hebron
Barcelona , 08035, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid , 28040, Spain
Hospital Universitario Virgen de Valme
Sevilla , 41014, Spain
National Cheng Kung University Hospital
Tainan , 704, Taiwan
National Taiwan University Hospital
Taipei , 10002, Taiwan
Chang Gung Medical Foundation-Linkou Branch
Taoyuan , 333, Taiwan
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
Newcastle Upon Tyne , NE7 7, United Kingdom
Royal Cornwall Hospitals NHS Trust
Truro , TR1 3, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 3

Estimated Enrollment:

262

Study ID:

NCT05059522

Recruitment Status:

Recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.